Bridging therapy: A challenging area in the management of patients with atrial fibrillation

American Journal of Cardiovascular Drugs

Volumn 13, Issue 4, 2013, Pages 259-261

  Guo, Yutao ^a,b   Lip, Gregory Y H ^a   Apostolakis, Stavros ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; APIXABAN; ARGATROBAN; DABIGATRAN; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRIDGING THERAPY; CARDIAC PATIENT; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; DIABETES MELLITUS; ELECTIVE SURGERY; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INTERNATIONAL NORMALIZED RATIO; LENGTH OF STAY; NOTE; PACEMAKER; PERCUTANEOUS CORONARY INTERVENTION; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RISK ASSESSMENT; STENT THROMBOSIS; THERAPY; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG MONITORING; FEMALE; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; WARFARIN;

EID: 84880912765     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-013-0032-5     Document Type: Note

References (23)

1. Kirchhof P, Lip GY, Van Gelder IC, et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options. Executive summary of the report from the III AFNET/EHRA consensus conference. Thromb Haemost. 2011;106:1012-9.
2. Douketis JD. Contra: Bridging anticoagulation is needed during warfarin interruption when patients require elective surgery. Thromb Haemost. 2012;108:210-2.
3. Spyropoulos AC. Pro: Bridging anticoagulation is needed during warfarin interruption in patients who require elective surgery. Thromb Haemost. 2012;108:213-6.
4. Omran H, Bauersachs R, Rübenacker S, et al. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation: results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thromb Haemost. 2012;108:65-73.
5. Smoyer-Tomic K, Siu K, Walker DR, Johnson BH, Smith DM, Sander S, Amin A. Anticoagulant use, the prevalence of bridging, and relation to length of stay among hospitalized patients with non-valvular atrial fibrillation. Am J Cardiovasc Drugs. 2012;12(6):403-13. doi: 10.2165/11633750-000000000-00000.
6. Faxon DP, Eikelboom JW, Berger PB, et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost. 2011;106:572-84.
7. Huber K, Airaksinen KJ, Cuisset T, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost. 2011;106(4):569-71.
8. Lip GY, Huber K, Andreotti F, et al. European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost. 2010;103:13-28.
9. Lip GY, Andreotti F, Fauchier L, et al. European Heart Rhythm Association. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost. 2011;106:997-1011.
10. Douketis JD, Spyropoulos AC, Spencer FA, et al. American College of Chest Physicians. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141: e326S-50S.
11. Olesen JB, Torp-Pedersen C, Hansen ML, et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost. 2012; 107(6) 1172-9.
12. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. 2012;14(4):528-606.
13. Goldstein JN, Greenberg SM. Should anticoagulation be resumed after intracerebral hemorrhage? Cleve Clin J Med. 2010;77:791-9.
14. Laux V, Perzborn E, Heitmeier S, et al. Direct inhibitors of coagulation proteins: the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? Thromb Haemost. 2009;102:892-9.
15. Eslam RB, Reiter N, Kaider A, et al. High-shear-and-thrombin-inducible platelet adhesion and aggregation in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin versus bivalirudin. Thromb Haemost. 2011;105:496-500.
16. De Luca G, Cassetti E, Verdoia M, et al. Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: a meta-analyis of randomised trials. Thromb Haemost. 2009;102:428-36.
17. Pengo V, Crippa L, Falanga A, et al. Italian Federation of Thrombosis Centers. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost. 2011;106:868-76.
18. Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost. 2010;104:49-60.
19. Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116-27.
20. Maegdefessel L, Linde T, Krapiec F, et al. In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves. Thromb Res. 2010;126:e196-200.
21. Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost. 2010;104:1099-105.
22. Huisman MV, Lip GY, Diener HC, et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost. 2012;107(5):838-47.
23. Ahrens I, Lip GY, Peter K. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation? Thromb Haemost. 2011;105:574-8.